All Stories

  1. Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia
  2. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
  3. Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
  4. Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders
  5. A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
  6. Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction
  7. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial
  8. Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies‐ The ATHENA study
  9. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial (CME)
  10. Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation
  11. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation
  12. A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation
  13. Different doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation
  14. Intracranial haemorrhage in thrombocytopenic haematology patients—a nested case–control study: the InCiTe study protocol
  15. Does bleeding affect patient‐reported outcome measures in patients with myelodysplasia or hematologic malignancies: a systematic review
  16. Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders
  17. Clinical trials on platelets: recent studies and what next?
  18. A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers
  19. Pathogen-reduced platelets for the prevention of bleeding
  20. Haematological Disease
  21. Intracranial haemorrhage in thrombocytopenic haematology patients
  22. The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions
  23. WHO Classification of Leukemia
  24. FAB Classification of Leukemia
  25. Risk factors for bleeding in haematology patients with low platelet counts
  26. Platelet transfusions in haematology patients: are we using them appropriately?
  27. Faculty Opinions recommendation of The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia.
  28. Faculty Opinions recommendation of Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia.
  29. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation
  30. Anti-fibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders
  31. Platelet transfusions for patients with haematological malignancies: who needs them?
  32. Faculty Opinions recommendation of A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
  33. Pathogen-reduced platelets for the prevention of bleeding
  34. Faculty Opinions recommendation of Determination of acute lung injury after repeated platelet transfusions.
  35. Prophylactic platelet transfusions
  36. Faculty Opinions recommendation of Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
  37. Faculty Opinions recommendation of Dose of prophylactic platelet transfusions and prevention of hemorrhage.